FLT3/D835Y-IN-1 (10 mg/kg, IP, daily, 6 days per week) significantly suppresses tumor growth and exhibits potent antitumor activity against MOLM14-ITD/D835Y cells[1].
FLT3/D835Y-IN-1 (10 mg/kg, IV or Orally, single) displays extremely low AUC and high clearance[1].
Pharmacokinetic Parameters of FLT3/D835Y-IN-1 in ICR mice[1].
| Parameters | 13a |
| AUClast (ng*h/mL) | 1360 ± 110 |
| CL (L/h/kg) | 6.96 ± 0.66 |
| Vss (L/kg) | 14.8 ± 0.7 |
| T1/2 (h) | 1.5 ± 0.1 |
| Animal Model: | NOD/SCID mice (6 weeks, male, nine mice per group)[1] |
| Dosage: | 10 mg/kg |
| Administration: | IP, daily, 6 days per week, from day 7 to day 29 |
| Result: | Significantly suppressed tumor growth. |
| Animal Model: | ICR mice (7–8 weeks, male)[1] |
| Dosage: | 10 mg/kg, dissolved in a solution (10% DMSO, 40% PEG400, and 50% PBS) |
| Administration: | IV or Orally, single (Pharmacokinetic Analysis) |
| Result: | Displayed extremely low AUC and high clearance. |
